A news article previewing first-in-human single-ascending-dose clinical data for a long-acting intravenous tuberculosis therapeutic, inviting readers to learn about safety, pharmacokinetics, and early clinical signals.
Key Takeaways
- AKG-100 was well tolerated across all SAD dose levels with no participant discontinuations
- Single-dose pharmacokinetics maintained drug concentrations above the target for at least 14 days
- Modelled EBA in tuberculosis patients estimated a 3.7 log10 bacterial reduction by day 14